Case Report

Synchronous oligometastases in cervical cancer: a case report

DOI: 10.1080/20742835.2018.1491139
Author(s): BT GuzhaDivision of Gynaecology Oncology, Department of Obstetrics and Gynaecology, South Africa, N NgxolaDivision of Gynaecology Oncology, Department of Obstetrics and Gynaecology, South Africa, T AdamsDivision of Gynaecology Oncology, Department of Obstetrics and Gynaecology, South Africa, L RogersDivision of Gynaecology Oncology, Department of Obstetrics and Gynaecology, South Africa, N MbataniDivision of Gynaecology Oncology, Department of Obstetrics and Gynaecology, South Africa, H-T WuSouth African Medical Research Council (SAMRC)/University of Cape Town (UCT) Gynaecological Cancer Research Centre, Cape Town, South Africa,, N FakieSouth African Medical Research Council (SAMRC)/University of Cape Town (UCT) Gynaecological Cancer Research Centre, Cape Town, South Africa,, V MuzendaDepartment of Radiology, South Africa, LA DennyDivision of Gynaecology Oncology, Department of Obstetrics and Gynaecology, South Africa

Abstract

Incidence and mortality of cervical cancer in South Africa is still very high and 4-6% of women present with FIGO stage IVB disease. However, the management of oligometastatic cervical cancer is not well decribed in literature. Treatment of stage IVB cervical cancer is individualised, but it mainly involves palliative systemic chemotherapy with a median survival time of about ten months. There is a growing body of evidence showing that in women with low volume oligometastatic disease, curative doses of radiation therapy to the pelvis and metastatic sites with or without chemotherapy can prolong survival significantly. Since South Africa is one of the few countries in Africa with functional chemoradiation therapy facilities, there is a need to review this evidence and see if the standard of care has to be changed in women with oligometastatic cervical cancer.

Get new issue alerts for Southern African Journal of Gynaecological Oncology